Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top-Down” approach to intestinal fibrosis in mice
Open Access
- 1 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 18 (3), 460-471
- https://doi.org/10.1002/ibd.21812
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in miceComparative Immunology, Microbiology and Infectious Diseases, 2011
- Review article: remission rates achievable by current therapies for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- Trends in Surgery for Crohn's Disease in the Era of InfliximabAnnals of Surgery, 2010
- Proinflammatory cytokines underlying the inflammation of Crohnʼs diseaseCurrent Opinion in Gastroenterology, 2010
- Can We Modulate the Clinical Course of Inflammatory Bowel Diseases by Our Current Treatment Strategies?Digestive Diseases, 2009
- Medical Management of Crohn’s Disease: Treatment Algorithms 2009Digestive Diseases, 2009
- Top-Down Therapy: Is the Evidence Strong Enough?Digestive Diseases, 2009
- Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's diseaseGut, 2009
- Chemically induced mouse models of intestinal inflammationNature Protocols, 2007
- Review article: altering the natural history of Crohn's disease – evidence for and against current therapiesAlimentary Pharmacology & Therapeutics, 2006